1. Repositório Institucional da UFMG
  2. Publicações Científicas e Culturais
  3. Artigo de Periódico
Please use this identifier to cite or link to this item: http://hdl.handle.net/1843/61841
Full metadata record
DC FieldValueLanguage
dc.creatorLigia Yukie Sassakipt_BR
dc.creatorMarley Ribeiro Feitosapt_BR
dc.creatorCarlos Henrique Marques Dos Santospt_BR
dc.creatorManoel Alvaro de Freitas Lins Netopt_BR
dc.creatorAbel Botelho Quaresmapt_BR
dc.creatorSergio Figueiredo de Lima Juniorpt_BR
dc.creatorGraciana Bandeira Salgado de Vasconcelospt_BR
dc.creatorOrnella Sari Cassolpt_BR
dc.creatorArlene Dos Santos Pintopt_BR
dc.creatorGustavo Kurachipt_BR
dc.creatorFrancisco de Assis Goncalves Filhopt_BR
dc.creatorDaniela Oliveira Magropt_BR
dc.creatorRodrigo Galhardi Gasparinipt_BR
dc.creatorThaísa Kowalski Furlanpt_BR
dc.creatorWilson Roberto Catapanipt_BR
dc.creatorCláudio Saddy Rodrigues Coypt_BR
dc.creatorVivian de Souza Menegassipt_BR
dc.creatorMarilia Majeski Colombopt_BR
dc.creatorRenata de sá Brito Fróespt_BR
dc.creatorFabio Vieira Teixeirapt_BR
dc.creatorAntonio Carlos Moraespt_BR
dc.creatorGenoile Oliveira Santanapt_BR
dc.creatorRogerio Saad-hossnept_BR
dc.creatorJosé Miguel Luz Parentept_BR
dc.creatorEduardo Garcia Vilelapt_BR
dc.creatorNatália Sousa Freitas Queirozpt_BR
dc.creatorPaulo Gustavo Kotzept_BR
dc.creatorJulio Pinheiro Baimapt_BR
dc.creatorCristina Florespt_BR
dc.creatorLucianna Motta Correiapt_BR
dc.creatorLívia Medeiros Soares Celanipt_BR
dc.creatorMaria de Lourdes de Abreu Ferraript_BR
dc.creatorPatricia Zachariaspt_BR
dc.date.accessioned2023-12-07T21:25:38Z-
dc.date.available2023-12-07T21:25:38Z-
dc.date.issued2022-05-29-
dc.citation.volume22pt_BR
dc.citation.issue268pt_BR
dc.citation.spage1pt_BR
dc.citation.epage12pt_BR
dc.identifier.doihttps://doi.org/10.1186/s12876-022-02341-7pt_BR
dc.identifier.issn1471-230Xpt_BR
dc.identifier.urihttp://hdl.handle.net/1843/61841-
dc.description.resumoBackground Anti-TNF therapy represented a landmark in medical treatment of ulcerative colitis (UC). There is lack of data on the efficacy and safety of these agents in Brazilian patients. The present study aimed to analyze rates of clinical and endoscopic remission comparatively, between adalimumab (ADA) and infliximab (IFX), in Brazilian patients with UC, and evaluate factors associated with clinical and endoscopic remission after 1 year of treatment. Methods A national retrospective multicenter study (24 centers) was performed including patients with UC treated with anti-TNF therapy. Outcomes as clinical response and remission, endoscopic remission and secondary loss of response were measured in different time points of the follow-up. Baseline predictive factors of clinical and endoscopic remission at week 52 were evaluated using logistic regression model. Indirect comparisons among groups (ADA and IFX) were performed using Student's t, Pearson χ2 or Fisher's exact test when appropriated, and Kaplan Meier analysis. Results Overall, 393 patients were included (ADA, n = 111; IFX, n = 282). The mean age was 41.86 ± 13.60 years, 61.58% were female, most patients had extensive colitis (62.40%) and 19.39% had previous exposure to a biological agent. Overall, clinical remission rate was 66.78%, 71.62% and 82.82% at weeks 8, 26 and 52, respectively. Remission rates were higher in the IFX group at weeks 26 (75.12% vs. 62.65%, p < 0.0001) and 52 (65.24% vs. 51.35%, p < 0.0001) when compared to ADA. According to Kaplan–Meier survival curve loss of response was less frequent in the Infliximab compared to Adalimumab group (p = 0.001). Overall, endoscopic remission was observed in 50% of patients at week 26 and in 65.98% at week 52, with no difference between the groups (p = 0.114). Colectomy was performed in 23 patients (5.99%). Age, non-prior exposure to biological therapy, use of IFX and endoscopic remission at week 26 were associated with clinical remission after 52 weeks. Variables associated with endoscopic remission were non-prior exposure to biological therapy, and clinical and endoscopic remission at week 26. Conclusions IFX was associated with higher rates of clinical remission after 1 year in comparison to ADA. Non-prior exposure to biological therapy and early response to anti-TNF treatment were associated with higher rates of clinical and endoscopic remission.pt_BR
dc.format.mimetypepdfpt_BR
dc.languageengpt_BR
dc.publisherUniversidade Federal de Minas Geraispt_BR
dc.publisher.countryBrasilpt_BR
dc.publisher.departmentMED - DEPARTAMENTO DE CLÍNICA MÉDICApt_BR
dc.publisher.departmentMEDICINA - FACULDADE DE MEDICINApt_BR
dc.publisher.initialsUFMGpt_BR
dc.relation.ispartofBMC Gastroenterologypt_BR
dc.rightsAcesso Abertopt_BR
dc.subjectAnti-TNF therapypt_BR
dc.subjectAdalimumabpt_BR
dc.subjectInfiximabpt_BR
dc.subjectClinical remissionpt_BR
dc.subjectUlcerative colitispt_BR
dc.subject.otherColite Ulcerativapt_BR
dc.subject.otherAdalimumabpt_BR
dc.subject.otherBrasilpt_BR
dc.titleAnti-TNF therapy for ulcerative colitis in Brazil: a comparative real-world national retrospective multicentric study from the Brazilian study group of IBD (GEDIIB)pt_BR
dc.typeArtigo de Periódicopt_BR
dc.url.externahttps://bmcgastroenterol.biomedcentral.com/articles/10.1186/s12876-022-02341-7pt_BR
dc.identifier.orcidhttp://orcid.org/0000-0002-7319-8906pt_BR
dc.identifier.orcidhttp://orcid.org/0000-0002-8180-6254pt_BR
dc.identifier.orcidhttp://orcid.org/0000-0002-8166-0304pt_BR
dc.identifier.orcidhttp://orcid.org/0000-0002-4035-3113pt_BR
dc.identifier.orcidhttp://orcid.org/0000-0003-1623-4525pt_BR
dc.identifier.orcidhttp://orcid.org/0000-0002-5621-2657pt_BR
dc.identifier.orcidhttp://orcid.org/0000-0002-2122-5538pt_BR
dc.identifier.orcidhttp://orcid.org/0000-0002-7890-0848pt_BR
dc.identifier.orcidhttp://orcid.org/0000-0002-4440-2023pt_BR
dc.identifier.orcidhttp://orcid.org/0000-0002-1181-7329pt_BR
dc.identifier.orcidhttp://orcid.org/0000-0003-1903-844Xpt_BR
dc.identifier.orcidhttp://orcid.org/0000-0002-3985-7402pt_BR
dc.identifier.orcidhttp://orcid.org/0000-0002-1250-2628pt_BR
dc.identifier.orcidhttp://orcid.org/0000-0002-2132-8780pt_BR
dc.identifier.orcidhttp://orcid.org/0000-0003-0867-6593pt_BR
dc.identifier.orcidhttp://orcid.org/0000-0001-7509-7730pt_BR
dc.identifier.orcidhttp://orcid.org/0000-0003-0344-9631pt_BR
dc.identifier.orcidhttp://orcid.org/0000-0003-0153-4349pt_BR
dc.identifier.orcidhttp://orcid.org/0000-0002-1032-5349pt_BR
dc.identifier.orcidhttp://orcid.org/0000-0002-9516-0378pt_BR
dc.identifier.orcidhttp://orcid.org/0000-0002-0412-2182pt_BR
dc.identifier.orcidhttp://orcid.org/0000-0002-0916-4138pt_BR
dc.identifier.orcidhttp://orcid.org/0000-0003-3046-2399pt_BR
dc.identifier.orcidhttp://orcid.org/0000-0001-6684-8061pt_BR
dc.identifier.orcidhttp://orcid.org/0000-0003-3256-4698pt_BR
dc.identifier.orcidhttp://orcid.org/0000-0002-8915-7279pt_BR
dc.identifier.orcidhttp://orcid.org/0000-0002-5533-5401pt_BR
dc.identifier.orcidhttp://orcid.org/0000-0003-4563-2784pt_BR
dc.identifier.orcidhttp://orcid.org/0000-0002-5443-7553pt_BR
dc.identifier.orcidhttp://orcid.org/0000-0003-2857-0825pt_BR
dc.identifier.orcidhttp://orcid.org/0000-0002-2053-5315pt_BR
Appears in Collections:Artigo de Periódico

Files in This Item:
File Description SizeFormat 
Anti-TNF therapy for ulcerative colitis in Brazil_ a comparative real-world national retrospective multicentric study from the Brazilian study group of IBD (GEDIIB).pdf328.19 kBAdobe PDFView/Open
Show simple item record


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.